13 (13) News
Track canonical SquawkNews coverage tagged to 13, 13. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Hutchmed (China) gets NMPA conditional approval for Atled in China
Hutchmed (China) announced NMPA conditional approval for Atled (fantegratinib) in China.
GEOPOLITICS | Aug 28, 2026, 12:38 AM UTC
M
Hutchmed gets NMPA approval for ATLED in FGFR2+ intrahepatic cholangiocarcinoma
HUTCHMED announced NMPA approval for ATLED (fanregratinib) for patients with FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.
EQUITY | Aug 28, 2026, 12:07 AM UTC